Skip to main content
Satellos Bioscience Inc. logo

Satellos Bioscience Inc. — Investor Relations & Filings

Ticker · MSCL ISIN · CA80401L3083 TSX Professional, scientific and technical activities
Open in API
Filings indexed 216 across all filing types
Latest filing 2026-04-17 Regulatory Filings
Country CA Canada
Listing TSX MSCL

About Satellos Bioscience Inc.

https://satellos.com/

Satellos Bioscience Inc. is a clinical-stage biotechnology company focused on developing regenerative small molecule therapeutics for degenerative muscle diseases, primarily Duchenne muscular dystrophy (DMD). The company's core mission is to restore the body's natural ability to regenerate muscle, addressing the failure of muscle repair inherent in these conditions. Satellos utilizes a novel approach rooted in muscle biology, focusing on restoring the asymmetric division of muscle stem cells (satellite cells), a process disrupted by the absence of dystrophin in DMD. Their strategy involves targeting the AAK1 protein to reactivate the natural repair mechanism. The lead therapeutic candidate, SAT-3247, is currently advancing into a Pediatric Phase 2 clinical study for DMD.

Recent filings

Filing Released Lang Actions
Notice of the meeting and record date - English.pdf
Regulatory Filings
2026-04-17 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a press release announcing Satellos Bioscience’s upcoming presentation at the Bloom Burton & Co. Healthcare Investor Conference (date, time, webcast details, company overview). It does not include financial results, a detailed presentation deck, or a formal investor presentation itself, nor does it report voting, dividends, or other structured filings. It is a general corporate announcement that does not align with any specific category, so it falls into the fallback “Regulatory Filings” category (RNS).
2026-04-09 English
News release - English.pdf
Investor Presentation Classification · 1% confidence The document is a press release announcing that Satellos Bioscience will present at the Bloom Burton & Co. Healthcare Investor Conference, providing details on date, format, and presenters. It is not financial results, a regulatory filing, or a share transaction; rather it is an announcement of an investor-facing presentation. Therefore it best fits the “Investor Presentation” category (IP).
2026-04-09 English
Material change report - English.pdf
Regulatory Filings Classification · 1% confidence The document is a 'Consent of Qualified Person' letter filed in relation to a technical report and a preliminary prospectus. It is a formal legal/regulatory filing required by securities commissions to validate technical disclosures. Since it does not fit into specific categories like financial reports, earnings, or shareholder voting, and serves as a formal regulatory submission, it is best classified as a Regulatory Filing (RNS).
2026-02-13 English
Underwriting or agency agreements (or amendment thereto).pdf
Capital/Financing Update Classification · 1% confidence The document is an 'Underwriting Agreement' between Satellos Bioscience Inc. and Leerink Partners LLC. It details the terms, conditions, and legal representations for a public offering of common shares and pre-funded warrants. This type of document is a standard legal contract associated with capital raising activities and securities offerings. Since it is not a report itself but a legal agreement governing the issuance of capital, it falls under the category of capital/financing updates.
2026-02-06 English
Prospectus (non pricing) supplement (other than ATM) – English.pdf
Capital/Financing Update Classification · 1% confidence The document is a 'Prospectus Supplement' for a public offering of common shares and pre-funded warrants by Satellos Bioscience Inc. It details the offering price, aggregate gross proceeds, underwriting agreements, and listing applications on the TSX and Nasdaq. This document is a formal regulatory filing related to capital raising and financing activities, which falls under the 'Capital/Financing Update' category.
2026-02-06 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.